A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

The study is a randomized, double-blind, and positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E as booster compared with Comirnaty. The study is a randomized, double-blind, and positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E as booster compared with Comirnaty (the COVID-19 vaccine from Pfizer-BioNTech).